These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14633154)

  • 1. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
    Osanai T; Nakamura M; Sasaki S; Tomita H; Saitoh M; Osawa H; Yamabe H; Murakami S; Magota K; Okumura K
    Kidney Int; 2003 Dec; 64(6):2291-7. PubMed ID: 14633154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma level of mitochondrial coupling factor 6 increases in patients with type 2 diabetes mellitus.
    Li XL; Xing QC; Dong B; Gao YY; Xing SS; Pang YZ; Jiang HF; Tang CS
    Int J Cardiol; 2007 May; 117(3):411-2. PubMed ID: 16899312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma mitochondrial coupling factor 6 in patients with acute myocardial infarction.
    Ding WH; Chu SY; Jiang HF; Cai DY; Pang YZ; Tang CS; Qi YF
    Hypertens Res; 2004 Oct; 27(10):717-22. PubMed ID: 15785006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma level of mitochondrial coupling factor 6 increases in patients with coronary heart disease.
    Chai SB; Hui YM; Li XM; Tang CS
    Circ J; 2007 May; 71(5):693-7. PubMed ID: 17456993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine.
    Tanaka M; Osanai T; Murakami R; Sasaki S; Tomita H; Maeda N; Satoh K; Magota K; Okumura K
    J Hypertens; 2006 Mar; 24(3):489-97. PubMed ID: 16467652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
    Zoccali C; Bode-Böger S; Mallamaci F; Benedetto F; Tripepi G; Malatino L; Cataliotti A; Bellanuova I; Fermo I; Frölich J; Böger R
    Lancet; 2001 Dec 22-29; 358(9299):2113-7. PubMed ID: 11784625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.
    Mallamaci F; Tripepi G; Maas R; Malatino L; Böger R; Zoccali C
    J Am Soc Nephrol; 2004 Feb; 15(2):435-41. PubMed ID: 14747391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
    Testa A; Spoto B; Tripepi G; Mallamaci F; Malatino L; Fatuzzo P; Maas R; Boeger R; Zoccali C
    J Hypertens; 2005 Oct; 23(10):1825-30. PubMed ID: 16148605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
    Shafi T; Hostetter TH; Meyer TW; Hwang S; Hai X; Melamed ML; Banerjee T; Coresh J; Powe NR
    Am J Kidney Dis; 2017 Jul; 70(1):48-58. PubMed ID: 28089476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coupling Factor 6 Is Upregulated in Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.
    Li N; Yin J; Cai W; Liu J; Zhang N; Yan S; Song L; Li X
    Am J Med Sci; 2016 Dec; 352(6):631-636. PubMed ID: 27916219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
    Thaha M; Widodo ; Pranawa W; Yogiantoro M; Tomino Y
    Clin Nephrol; 2008 Jan; 69(1):24-32. PubMed ID: 18226399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
    Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
    Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
    El Shahawy Y; Soliman Y; Rifaie A; Shenawy H; Behairy M; Mady G
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):26-33. PubMed ID: 25579712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
    Zhang WR; Tao LJ; Chen BM
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):133-4. PubMed ID: 12575339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH
    Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.